UNITAID / PFIZER LICENSING AGREEMENT

Preview Language:   Original
16-Nov-2021 00:02:59
UNITAID Medicines Patent Pool (MPP) today announced a voluntary license agreement for Pfizer’s COVID-19 oral antiviral treatment candidate PF-07321332, which is administered in combination with low dose ritonavir. UNITAID

Available Language: English
Type
Language
Format
Acquire
/
English
Other Formats
Description
STORY: UNITAID / PFIZER LICENSING AGREEMENT
TRT: 02:59
SOURCE: UNITAID
RESTRICTIONS: NONE
LANGUAGE: ENGLISH / NATS

DATELINE: 16 NOVEMBER 2021 GENEVA, SWITZERLAND (UNITAID AND MEDICINES PATENT POOL) / FILE


SHOTLIST:

FILE – ALIMA - GBESSIA, GUINEA

1. Wide shots, exterior, Outside the Epidemiological Treatment Centre in Gbessia, Guinea.

UNITAID - 16 NOVEMBER 2021, GENEVA, SWITZERLAND

2. SOUNDBITE (English) Hervé Verhoosel, Spokesperson, Unitaid:
“Today, the Medicines Patent Pool (MPP), which was created by health agency Unitaid to increase access to medicines for low- and middle-income countries, is announcing a voluntary license agreement for Pfizer’s COVID-19 oral antiviral treatment candidate, which is administered in combination with low dose ritonavir.”

FILE – ALIMA - GBESSIA, GUINEA

3. Wide shot, exterior, COVID-19 triage zone at the Epidemiological Treatment Centre in Gbessia, Guinea.

UNITAID - 16 NOVEMBER 2021, GENEVA, SWITZERLAND

4. SOUNDBITE (English) Charles Gore, Executive Director, Medicines Patent Pool:
“This license is very important, because the drug is particularly suited for low- and middle-income countries. It’s easy to produce. It’s an oral medicine, so it’s potentially easy to take and it doesn’t need to be taken in a hospital setting. That means that, assuming its approved, this could make a major contribution to saving lives in low- and middle-income countries.”

FILE – ALIMA - GBESSIA, GUINEA

5. Various shots, interior, a coughing man is examined by a physician at the Epidemiological Treatment Centre in Gbessia, Guinea.

UNITAID - 16 NOVEMBER 2021, GENEVA, SWITZERLAND
6. SOUNDBITE (English) Hervé Verhoosel, Spokesperson, Unitaid:
“Under the terms of the head license agreement between Pfizer and MPP, selected generic medicine manufacturers worldwide that are granted sub-licenses will be able to supply the drugs to 95 countries, covering up to approximately 53 of per cent the world’s population. This includes all low- and lower-middle-income countries.” […] “Today, Unitaid urges all pharmaceutical companies to commit to improve global and equitable access to all new tools and treatments in the countries most affected by the pandemic.”

FILE – ALIMA - GBESSIA, GUINEA

7. Various shots, interior, at the Epidemiological Treatment Centre in Gbessia, Guinea, a doctor asks a patient some health questions and provides him with COVID-19-related psychosocial support.


STORYLINE:

UNITAID Medicines Patent Pool (MPP) today (16 Nov) announced a voluntary license agreement for Pfizer’s COVID-19 oral antiviral treatment candidate PF-07321332, which is administered in combination with low dose ritonavir.
Medicines Patent Pool (MPP) was created by Unitaid to increase access to life-saving medicines for low- and middle-income countries.

The agreement will enable MPP to facilitate additional production and distribution of the investigational antiviral, pending regulatory authorization or approval, by granting sub-licenses to qualified generic medicine manufacturers, with the goal of facilitating greater access to the global population.

Under the terms of the head license agreement between Pfizer and MPP, qualified generic medicine manufacturers worldwide that are granted sub-licenses will be able to supply the new drug in combination with ritonavir to 95 countries, covering up to approximately 53% of the world’s population. This includes all low- and lower-middle-income countries and upper-middle-income countries in Sub-Saharan Africa as well as upper-middle-income countries that have transitioned to upper-middle-income status in the past five years. Pfizer will not receive royalties on sales in low-income countries and will further waive royalties on sales in all countries covered by the agreement while COVID-19 remains classified as a Public Health Emergency of International Concern by the World Health Organization.

This is the first licence allowing generic manufacturing of this drug. It is an important first step to help ensure that the latest tools for fighting COVID-19 are available in low- and middle-income countries at the same time as they become available in the wealthiest nations.

Unitaid is committed to creating equitable access for health innovations for people everywhere and founded MPP ten years ago to help achieve that goal. Voluntary licences secured with support from Unitaid and MPP have proven successful in strengthening responses to other global health challenges including HIV by making generic antiretroviral medicines widely available in countries with limited resources.

The Access to COVID-19 Tools Accelerator has estimated that millions of people in low- and middle-income countries are at-risk of mild to moderate COVID-19. As co-lead of the ACT-A therapeutics pillar, Unitaid and partners are working to ensure equitable and rapid access to new treatments. To achieve this, multiple generic manufacturers must be ready to supply products to meet potential high demand, as soon as the new drug is approved by regulatory authorities.

Unitaid urges all pharmaceutical companies to commit to improve global access to all new tools and treatments in the countries most affected by the pandemic.

Unitaid is a global health agency engaged in finding innovative solutions to prevent, diagnose, and treat diseases more quickly, cheaply, and effectively, in low- and middle-income countries. Our work includes funding initiatives to address major diseases such as HIV/AIDS, malaria, and tuberculosis, as well as HIV co-infections and co-morbidities such as cervical cancer and hepatitis C, and cross-cutting areas, such as fever management.
Unitaid is now applying its expertise to address challenges in advancing new therapies and diagnostics for the COVID-19 pandemic, serving as a key member of the Access to COVID-19 Tools (ACT) Accelerator. Unitaid is hosted by the World Health Organization.

The Medicines Patent Pool (MPP) was created by Unitaid in 2010 to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organizations, industry, patient groups, and other stakeholders, to prioritize and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations. To date, MPP has signed agreements with eleven patent holders for thirteen HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a long-acting technology and two experimental oral antiviral treatments for COVID-19. MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC). MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government and SDC.
Series
Category
Geographic Subjects
Creator
UNITAID
Alternate Title
unifeed211116e
Asset ID
2687010